

Ticker: NICU CN

2Q24 Cash: C\$4m

Project: Sudbury Assets

Market cap: C\$204m

Price: C\$1.20/sh

Country: Canada, ON

REC. (unc): BUY

TARGET (+1.65): C\$3.25/sh

RISK RATING (from SPEC.): HIGH

Very simply, we think yesterday's KGHM asset acquisition is entirely transformative for Magna. Key here is that the acquired Sudbury assets will be back in the hands of the original exploration and development team that first discovered and put them into production >15 years ago— providing unparalleled upside in our view. Further, **Magna will immediately become a copper producer** and should benefit from i) a nearterm re-rate with copper producers/developers notably trading up to 1.8xNAV, ii) FCFs to support ongoing capital development and exploration activities, and iii) the synergies of acquiring an operating mine (incl. skilled workforce/environmental group/H&S) useful for developing the company's growth prospects (e.g. operating three mines in 3-5 years). While subject to standard conditions, the acquisition close could come as early as 4Q24, lifting global resources from 56mt @ 1.3% NiEq (713kt contained) to SCPe 82Mt @ 1.5% NiEq (1.3Mt contained; incl. historic), only a discovery away from rivalling Glencore's 2.0Mt contained NiEq (all @ spot), something we think is likely given the slew of high-caliber asset pick-up's yesterday with plenty of juice left to squeeze, making Magna one of few junior high-grade >1.0Mt contained nickel sulphide projects globally.

We expect guidance on production, expansion opportunities and costs to be given after closing. For now, we update for 2Q24 cash and shares, add producing McCreedy West Mine (Dec23 43-101) to our valuation at a nominal 5% in-situ value and incorporate Historic Resources (Dec22) to our resources excluding inventory at 1% in-situ, and apply a 0.7x NAV multiple until the deal closes, leaving room for upside. As such, we maintain our BUY rating and lift our price target from C\$1.60/sh to C\$3.25/sh at 0.7xNAV $_{7\%-9.50}$  for a C\$748m Crean Hill only UG and OP scenario. Magna trades cheaply at just 0.2xNAV well below the peer group – this is where the fun starts.

Management continues to 'do what they say' and execute on their objectives at an extreme pace — becoming a producing company in ~2Y post step-change Crean Hill acquisition and maintaining their trajectory towards being a multi-asset producer — making them the only junior critical minerals producer in Sudbury — one of the best mining jurisdictions globally. Upcoming news flow remains thick with results from drilling and surface bulk sample processing tests, kicking-off UG advanced exploration, a PEA/MRE update, and transaction close all ahead, with key next step securing funding ahead of test mining.

M NORTHWESTFOY

M NORTHRANGE

Figure 1: (A) regional plan of Magna's existing and acquiring assets & (B) McCreedy W copper mine

Source: Magna Mining

## Developer to copper producer with KGHM asset portfolio acquisition; SCPe PT up to C\$3.25/sh

Yesterday, Magna entered into a definitive share purchase agreement with FNX Mining, a subsidiary of KGHM, to acquire a portfolio of assets in the Sudbury Basin. These include the **McCreedy West operating copper mine** (2023 prod 317.7kt @ 3.4% CuEq (49-15-12-11-1; Cu-Pd-Pt-Ni-Au-Co)) with existing

Dec23 43-101 MRE of **9.5Mt** @ **2.4% NiEq (4.1% CuEq)** (38-31-10-9-9-2-1 Ni-Cu-Au-Pt-Pd-Co-Ag), past-producing Levack mine (C&M since 2019), Podolsky Mine (C&M since 2013), and Kirkwood Mine as well as Falconbridge Footwall (81.41%), Northwest Foy (81.41%), North Range and Rand exploration assets. Historical resources from Levack, Podolsky, Kirkwood total 17.0Mt @ 2.0% NiEq (3.4% CuEq).

As part of the transaction, Magna will acquire the outstanding shares of Project Nikolas Company Inc. (PNCI) from FNX Mining (KGHM sub) for C\$5.3m cash and C\$2.0m Magna shares on close, a deferred payment of C\$2.0m on 31 Dec 2026, and future contingent payments up to C\$24.0m. A 4% NSR royalty from FNX in place with right to buy back 3% for cash. To fund the transaction, Magna is negotiating a C\$10.0m three-year Term Loan Facility and a C\$10.0m Letter of Credit with FCDQ. Magna will assume PNCI reclamation liabilities of C\$9.9m. The transaction is subject to conditions with closing date expected in 4Q24-1Q25.

# Why we like Magna Mining Inc

- 1. High grade UG >2% NiEq complimented by permitted pits for scale
- 2. Vale 'ore sale' and Glencore 'toll-mill' agreements enables fast tracked production / advanced exploration
- 3. Tier-1/globally significant Ni sulphide district near hungry mills/smelters
- 4. Best in class Sudbury based technical team (formerly FNX Mining)

### **Catalysts**

- 2024: 25,000m drill program and results
- 3Q24: MRE/PEA update
- 2H24: UG portal development
- 4Q24-1Q25: Acquisition close for select KGHM assets

#### Research

**Brandon Gaspar** (Toronto) m +1 437 533 3142 <u>bgaspar@scp-rf.com</u> **Eleanor Magdzinski** (Toronto) m +1 705 669 7456 <u>emagdzinski@scp-rf.com</u> **Omeet Singh** (Toronto) m +1 647 527 7509 <u>osingh@scp-rf.com</u>



Ticker: NICU CN Author: B Gaspar	Price / mk Rec / PT:	п сар:	C\$1.2/sh, BUY, C\$3.			P/NAV today: 1 1xNAV7%: 1			Country: (	Canada, C Sudbury	
Commodity price	CY22E	CY23E	CY24E	CY25E	CY26E	Resource/Inventory @ SCP LT px	Mt	NiEq %	Sudbury	Mt	NiEq %
Ni price (US\$/t)	20,944	20,944	20,944	20,944	20,944	Shakespeare pit reserve	12 Mt	0.7%	Pit M&I&I	34 Mt	0.8%
Ni price (US\$/t, payable)	11,352	11,352	11,352	11,352	11,352	SCPe Crean Hill OP inventy	6 Mt	0.7%	UG M&I&I*	48 Mt	1.7%
Share data (m)	Basic	FD	FF FD	11,002	11,002	SCPe Crean Hill UG inventy	11 Mt	2.1%	Total*	82 Mt	1.4%
Shares (m)	170.4	209.8	329.0			Total	29 Mt	1.2%	*incl. Histori		
SOTP project valuation*	170.1	C\$m	o/ship	NAVx	C\$/sh	Funding: uses	20 IVIC	1.270	Funding:		
Crean Hill NPV (build start)		633	100%	1.00x	3.02	Staged build capex Y3 (C\$m)	304	Cash+nre	prod'n ITM		6
McCreedy West nominal @ 5% in-situ		200	100%	1.00x	0.96	Exploration (C\$m)	8		evel SCPe d	,	198
Resources ex inventory @ 1% in-situ		122	100%	1.00x	0.58	UG dev. capex (C\$m)	56		xpansion equ	,	107
Cash 2Q24		4	100%	1.00x	0.02	SCPe G&A+fin. cost (C\$m)	5		pre-build equ		65
Cash from ITM options/warrants		16	100%	1.00x	0.08	SCPe FCF Y1-2 (C\$m)	(21)	00.0	Total source	, , ,	375
1XNAV C\$		976	1		4.65	Total uses: group (C\$m)	353		Buffer:	23	
*Build start, ex fin. cost + G&A, dil. for	ontns not bi			IAV today:	0.26x	Ratio analysis	CY22E	CY23E	CY24E	CY25E	CY26E
Asset value: 1xNPV project (C\$m,				today.	0.20%	Shares out (m)	146.9	163.4	170.4	170.4	244.4
Asset NPV (C\$m)	14,944	17,944	20,944	23,944	26,944	EPS (Cc/sh)	-	-	-	1.9	5.2
9.0% discount	319	415	512	608	704	CFPS before w/c (C\$/sh)	_	_	_	-	-
7.0% discount	407	520	633	746	859	EV (C\$m)	170.1	185.2	228.9	241.0	228.2
5.0% discount	520	654	787	921	1,054	FCF yield (%)	-	-	-	-	-
Ungeared project IRR:		35%	41%	47%	53%	Income statement	CY22E	CY23E	CY24E	CY25E	CY26E
Asset NPV (C\$/sh)	14,944	17,944	20,944	23,944	26,944	Revenue (C\$m)	-	-	-	50.9	67.9
9.0% discount	1.52	1.98	2.44	2.90	3.36	COGS (C\$m)	_	_	_	19.5	26.0
7.0% discount	1.94	2.48	3.02	3.56	4.09	Gross profit (C\$m)	-	-		31.4	41.9
5.0% discount	2.48	3.12	3.75	4.39	5.02	G&A (C\$m)	0.9	3.4	5.8	6.3	4.0
*Project level NPV, excl finance costs a					0.02	Exploration (C\$m)	1.1	7.8	10.9	11.0	11.0
Group valuation over time^	Sep-24	Sep-25	Sep-26	Sep-27	Sep-28	Finance costs (C\$m)	-	0.4	0.3	0.4	0.8
Project NPV (C\$m)	685	762	787	868	1,014	Tax (C\$m)	_	-	-	9.2	12.2
McCreedy West nominal @ 5% in-situ	200	200	200	200	200	Other (C\$m)	(0.0)	(1.7)	(0.7)	1.2	1.3
Resources ex inventory @ 1% in-situ	122	122	122	122	122	Net income (C\$m)	(2.0)	(9.9)	(16.3)	3.3	12.6
Central G&A and finance costs	(120)	(110)	(101)	(87)	(62)	Cash flow statement	CY22E	CY23E	CY24E	CY25E	CY26E
Net cash prior quarter	4	(41)	76	31	(80)	EBITDA (C\$m)	(1.9)	(10.3)	(16.2)	13.2	26.0
Cash from ITM options/warrants	16.4	16.4	16.4	16.4	16.4	Add share based (C\$m)	0.0	1.5	0.9	0.9	0.9
Total NAV (C\$m)	907	949	1,101	1,150	1,210	Net change wkg cap (C\$m)	0.2	0.3	(0.8)	8.8	-
FF FD share count (m)	210	210	284	284	284	Cash flow ops (C\$m)	(2.2)	(10.6)	(15.9)	(4.4)	14.0
1xNAV7%/sh FF FD (C\$/sh)	4.33	4.53	3.88	4.05	4.26	PP&E - build + sust. (C\$m)	(0.0)	(0.1)	(20.0)	(7.8)	(18.9)
Exit value: 1xNAV/sh company @ 2						PP&E - expl'n (C\$m)	(0.1)	-	-	-	-
1xNAV (C\$m)	14,944	17,944	20,944	23,944	26,944	Cash flow inv. (C\$m)	(0.1)	(0.1)	(20.2)	(7.8)	(18.9)
9.0% discount	527	682	837	989	1,141	Share issue (C\$m)	-	18.4	-	-	106.6
7.0% discount	608	779	949	1,118	1,286	Debt draw (repay) (C\$m)	_	-	(0.0)	_	49.5
5.0% discount	709	900	1,090	1,278	1,466	Cash flow fin. (C\$m)	(0.0)	15.4	0.8		156.0
1xNAV (C\$/sh)	14,944	17,944	20,944	23,944	26,944	Net change in cash (C\$m)	(2.1)	4.7	(35.3)	(12.2)	151.1
9.0% discount	2.51	3.25	3.99	4.72	5.44	Balance sheet	CY22E	CY23E	CY24E	CY25E	CY26E
7.0% discount	2.90	3.71	4.53	5.33	6.13	Cash (C\$m)	6.2	10.9	(24.4)	(36.6)	114.5
5.0% discount	3.38	4.29	5.20	6.10	6.99	Acc rec. + invet. (C\$m)	1.4	1.8	2.5	10.4	10.4
Production (Y1 from 2Q25)	CY25	CY26	CY27	CY28	CY29	PP&E & expl'n (C\$m)	0.1	0.1	37.6	45.1	63.5
SCPe production (000kt NiEg) <sup>^</sup>	2.4	3.2	11.7	11.7	14.6	Total assets (C\$m)	7.7	12.8	15.7	18.9	188.4
AISC Co-prod. (US\$/lb Ni)*	8	8	8	8	8	Debt (C\$m)	0.0	-	-	-	49.5
^CY25-28 toll milling; CY29 owner-ope				•		Accounts payable (C\$m)	1.7	1.6	3.1	2.1	2.1
Sudbury prod'n (Li		Eq) <b>→</b>	AISC (RHS	s, C\$/t NiEd	a) 00	Others (C\$m)	6.9	11.9	(22.9)	(27.1)	124.0
20kt					20	Total liabilities (C\$m)	5.1	5.4	5.5	4.5	54.0
15kt					15	Shareholders' equity (C\$m)	32.5	45.8	47.0	47.9	155.3
10kt 🔷 🔷	<b>*</b>		•	<b>-</b>	10	Reserves (C\$m)	3.2	4.4	4.9	4.9	4.9
5kt					5	Retained earnings (C\$m)	(33.0)	(42.9)	(41.7)	(38.4)	(25.8)
0kt	-	-	-		<b>→</b> -		(00.0)	(12.0)	( /	(55.7)	(20.0)

Source: SCP estimates, \*AISC done on ore selling NSR

#### **DISCLOSURES & DISCLAIMERS**

This research report (as defined under CIRO Rule 3600, Part B) is issued and approved for distribution in Canada by SCP Resource Finance LP ("SCP"), an investment dealer who is a member of the Canadian Investment Regulatory Organization (CIRO) and the Canadian Investor Protection Fund ("CIPF"). This research report is provided to retail clients and institutional investors for information purposes only. The opinions expressed in this report are the opinions of the author and readers should not assume they reflect the opinions or recommendations of SCP's research department. The information in this report is drawn from sources believed to be reliable but the accuracy or completeness of the information is not guaranteed, nor in providing it does SCP or persons assume any responsibility or liability whatsoever. This report is not to be construed as an offer to sell or a solicitation of an offer to buy any securities. SCP accepts no liability whatsoever for any loss arising from any use or reliance on this research report or the information contained herein. Past performance is not a guarantee of future results, and no representation or warranty, expressed or implied, is made regarding future performance of any security mentioned in this research report. The price of the securities mentioned in this research report and the income they generate may fluctuate and/or be adversely affected by market factors or exchange rates, and investors may realize losses on investments in such securities, including the loss of investment principal. Furthermore, the securities discussed in this research report may not be liquid investments, may have a high level of volatility or may be subject to additional and special risks associated with securities and investments in emerging markets and/or foreign countries that may give rise to substantial risk and are not suitable for all investors. SCP may participate in an underwriting of, have a position in, or make a market in, the securities mentioned herein, including options, futures or

**DISSEMINATION OF RESEARCH:** SCP's research is distributed electronically through email or available in hard copy upon request. Research is disseminated concurrently to a pre-determined list of clients provided by SCP's Institutional Sales Representative and retail Investment Advisors. Should you wish to no longer receive electronic communications from us, please contact <a href="mailto:unsubscribe@scp-rf.com">unsubscribe@scp-rf.com</a> and indicate in the subject line your full name and/or corporate entity name and that you wish to unsubscribe from receiving research.

**RESEARCH ANALYST CERTIFICATION:** Each Research Analyst and/or Associate who is involved in the preparation of this research report hereby certifies that:

- The views and recommendations expressed herein accurately reflect his/her personal views about any and all of the securities or issuers that are the subject matter of this research report;
- His/her compensation is not and will not be directly related to the specific recommendations or view expressed by the Research analyst in this research report;
- They have not affected a trade in a security of any class of the issuer within the 30-day period prior to the publication of this research report;
- They have not distributed or discussed this Research Report to/with the issuer, investment banking group or any other third party
  except for the sole purpose of verifying factual information; and
- They are unaware of any other potential conflicts of interest.

**UK RESIDENTS:** SCP Partners UK Limited ("SCP UK") is an appointed representative of PillarFour Securities LLP which is authorized and regulated by the Financial Conduct Authority. This document has been approved under section 21(1) of the FMSA 2000 by PillarFour Securities LLP ("PillarFour") for communication only to eligible counterparties and professional clients as those terms are defined by the rules of the Financial Conduct Authority. Its contents are not directed at UK retail clients. PillarFour does not provide investment services to retail clients. PillarFour publishes this document as non-independent research which is a marketing communication under the Conduct of Business rules. It has not been prepared in accordance with the regulatory rules relating to independent research, nor is it subject to the prohibition on dealing ahead of the dissemination of investment research. It does not constitute a personal recommendation and does not constitute an offer or a solicitation to buy or sell any security. SCP UK and PillarFour consider this note to be an acceptable minor non-monetary benefit as defined by the FCA which may be received without charge. This is because the content is either considered to be commissioned by SCP UK's clients as part of their advisory services to them or is short term market commentary. Neither SCP UK nor PillarFour nor any of its directors, officers, employees or agents shall have any liability, howsoever arising, for any error or incompleteness of fact or opinion in it or lack of care in its preparation or publication; provided that this shall not exclude liability to the extent that this is impermissible under the law relating to financial services. All statements and opinions are made as of the date on the face of this document and are not held out as applicable thereafter. This document is intended for distribution only in those jurisdictions where PillarFour is permitted to distribute its research.

IMPORTANT DISCLOSURES FOR U.S. PERSONS: This research report was prepared by SCP Resource Finance LP ("SCP"), a company authorized to engage in securities activities in Canada. SCP is not a registered broker/dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Sprott Global Resource Investments Ltd. ("SGRIL"), a broker dealer in the United States registered with the Securities Exchange Commission ("SEC"), the Financial Industry Authority ("FINRA"), and a member of the Securities Investor Protection Corporation ("SIPC"). Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through SCP.

SGRIL accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor. The analyst whose name appears in this research report is not licensed, registered, or qualified as a research analyst with FINRA and may not be an associated person of SGRIL and, therefore, may not be subject to applicable restrictions under FINRA Rule 2241 regarding communications by a research analyst with a subject company, public appearances by the research analyst, and trading securities held by a research analyst account. To make further inquiries related to this report, United States residents should contact their SGRIL representative.

**ANALYST CERTIFICATION / REGULATION AC:** The analyst and associate certify that the views expressed in this research report accurately reflect their personal views about the subject securities or issuers. In addition, the analyst and associate certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.



**SCP RESOURCE FINANCE EXPLANATION OF RECCOMENDATIONS:** Should SCP issue research with recommendations, the research rating guidelines will be based on the following recommendations:

**BUY:** The stocks total returns are expected to be materially better than the overall market with higher return expectations needed for more risky securities markets

**NEUTRAL**: The stock's total returns are expected to be in line with the overall market

**SELL:** The stocks total returns are expected to be materially lower than the overall market

TENDER: The analyst recommends tendering shares to a formal tender offering

**UNDER REVIEW:** The stock will be placed under review when there is a significant material event with further information pending; and/or when the research analyst determines it is necessary to await adequate information that could potentially lead to a reevaluation of the rating, target price or forecast; and/or when coverage of a particular security is transferred from one analyst to another to give the new analyst time to reconfirm the rating, target price or forecast.

NOT RATED (N/R): The stock is not currently rated

Research Disclosure				
1	1 SCP collectively beneficially owns 1% or more of any class of the issuer's equity securities <sup>1</sup>			
2	The analyst or any associate of the analyst responsible for the report or recommendation or any individual directly involved in the preparation of the report holds or is short any of the issuer's securities directly or through derivatives	NO		
3	An SCP partner, director, officer or analyst involved in the preparation of a report on the issuer, has during the preceding 12 months provided services to the issuer for remuneration other than normal course investment advisory or trading execution services	NO		
4	SCP has provided investment banking services for the issuer during the 12 months preceding the date of issuance of the research report or recommendation	NO		
5	Name of any director, officer, employee or agent of SCP who is an officer, director or employee of the issuer, or who serves in an advisory capacity to the issuer	NO		
6	SCP is making a market in an equity or equity related security of the issuer	NO		
7	The analyst preparing this report received compensation based upon SCP's investment banking revenue for the issuer	NO		
8	The analyst has conducted a site visit and has viewed a major facility or operation of the issuer	YES		
9	The analyst has been reimbursed for travel expenses for a site visit by the issuer	NO		

#### **SCP Resource Finance Equity Research Ratings:**

Summary of Recommendations as of September 2024				
BUY:	50			
HOLD:	0			
SELL:	0			
UNDER REVIEW:	0			
TENDER:	0			
NOT RATED:	0			
TOTAL	50			

<sup>&</sup>lt;sup>1</sup> As at the end of the month immediately preceding the date of issuance of the research report or the end of the second most recent month if the issue date is less than 10 calendar days after the end of the most recent month



Page 5